Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Histologic Remission in Ulcerative Colitis

Are We There Yet?

Long, Millie D. MD, MPH1; Rubin, David T. MD2

American Journal of Gastroenterology: May 2019 - Volume 114 - Issue 5 - p 713–715
doi: 10.14309/ajg.0000000000000235
EDITORIAL
Buy

As the field of inflammatory bowel disease moves toward treating to a “target” that includes mucosal healing, better outcome definitions are needed. One important question is whether the definition of mucosal healing should include “histologic” remission. In this systematic review and meta-analysis, the authors describe histologic healing rates of medical therapies for ulcerative colitis in randomized controlled trials. Although observational data demonstrate that histologic remission has consistently been associated with improved outcomes, we argue that there is a great deal of work left to be done before we can embrace a histologic endpoint of management in ulcerative colitis.

1Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Inflammatory Bowel Diseases Center, Chapel Hill, NC, USA;

2Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.

Correspondence: Millie D. Long, MD, MPH. E-mail: millie_long@med.unc.edu.

Received February 25, 2019

Accepted March 22, 2019

© The American College of Gastroenterology 2019. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website